LEO delivers double-digit growth ahead of 2026 IPO

26 February 2025

Danish dermatology specialist LEO Pharma has announced results showing a strong performance in 2024, with both sales growth and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin ahead of the initial outlook for the year.

Revenue grew 10% at constant exchange rates to 12.45 billion Danish kroner ($1.75 billion), while operating profit improved significantly, with adjusted EBITDA up 43% year-over-year to 895 million kroner.

This reflected margin expansion of 2% to 7%, despite LEO’s spending around the launch of the hand eczema treatment Anzupgo (delgocitinib) and the negative impact of foreign exchange rates.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK